Big Pharmacology’s version of fake news?

An article in Medscape points out the shoddy research and financial incentives for using research misinformation to publish guidelines for using antipsychotics in the treatment of children, adolescents and adults with common symptoms of depression. However this critique of antipsychotics usage is unlikely to stem the use of  advertising masquerading as research to promote disease mongering. This tactic had been very useful in the expansion of opioid prescriptions, which in 2016 resulted in 63,000 deaths by overdoses. Read more here:  Deep Dive Into Mixed Depression Guideline Raises Red Flags